Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Digoxin × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 6 Tumor-Agnostic 4 Gastrointestinal 4 Breast 4 Thoracic 3 Dermatologic 3 Head & Neck 2 Genitourinary 2 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Endocrine 1 CNS 1

Conditions

Medulloblastoma 1

Interventions

Temozolomide 607 Radiotherapy 387 Bevacizumab 251 Magnetic Resonance Spectroscopy 199 Cyclophosphamide 176 Carboplatin 159 Radiosurgery 145 Etoposide 132 Radiation 120 Irinotecan 115 Vincristine 114 Cisplatin 102 Filgrastim 100 Specimen Handling 87 Nivolumab 87 pembrolizumab 81 Lomustine 80 Surgical Procedures, Operative 73 Topotecan 72 Melphalan 59 Doxorubicin 59 Carmustine 57 sargramostim 53 Isotretinoin 53 Radiotherapy, Intensity-Modulated 52 Peripheral Blood Stem Cell Transplantation 52 Granulocyte Colony-Stimulating Factor 50 Erlotinib Hydrochloride 50 Everolimus 48 Chemotherapy, Adjuvant 48

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06701812 2026-02-27

Digoxin Medulloblastoma Study

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting

Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡